We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta
Read MoreHide Full Article
GlaxoSmithKline plc (GSK - Free Report) reported results from two pivotal phase III studies – SIRROUND-T and SIRROUND-H – on subcutaneous sirukumab (anti-interleukin-6 monoclonal antibody) for the treatment of adults with moderate to severely active rheumatoid arthritis (RA).
SIRROUND-T evaluated sirukumab in adult patients with moderate to severely active RA who are refractory or intolerant to one or more anti-tumor necrosis factor (TNF) agents. Results demonstrated that a significantly higher proportion of patients treated with sirukumab witnessed an at least 20% improvement in signs and symptoms (ACR20) at week 16 in comparison to placebo, thereby meeting the primary endpoint of the study.
On the other hand, the SIRROUND-H study compared sirukumab monotherapy with Abbvie, Inc.’s (ABBV - Free Report) Humira (adalimumab) monotherapy in adult patients with moderate to severely active RA who were refractory to, intolerant to or inappropriate for methotrexate. Results showed that sirukumab monotherapy achieved the first two co-primary endpoints, having led to a significant improvement in disease activity compared with Humira monotherapy.
We note that regulatory applications seeking approval for sirukumab for RA have been filed in both the U.S. and the EU.
Glaxo is developing sirukumab under a licensing and co-development agreement with Johnson & Johnson’s (JNJ - Free Report) Janssen Biologics.
In a separate press release, Glaxo announced data from a seven-year safety and efficacy continuation phase III study on Benlysta for the treatment of patients with active, autoantibody-positive systemic lupus erythematosus (SLE). Data showed that long-term control of disease activity in patients receiving Benlysta plus standard of care led to meaningful benefits in their daily lives, including improvements in health-related quality of life and fatigue.
Data from the studies on sirukumab and Benlysta will be presented at the annual meeting of the American College of Rheumatology/Association for Rheumatology Health Professionals.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has gained 17.1% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta
GlaxoSmithKline plc (GSK - Free Report) reported results from two pivotal phase III studies – SIRROUND-T and SIRROUND-H – on subcutaneous sirukumab (anti-interleukin-6 monoclonal antibody) for the treatment of adults with moderate to severely active rheumatoid arthritis (RA).
SIRROUND-T evaluated sirukumab in adult patients with moderate to severely active RA who are refractory or intolerant to one or more anti-tumor necrosis factor (TNF) agents. Results demonstrated that a significantly higher proportion of patients treated with sirukumab witnessed an at least 20% improvement in signs and symptoms (ACR20) at week 16 in comparison to placebo, thereby meeting the primary endpoint of the study.
On the other hand, the SIRROUND-H study compared sirukumab monotherapy with Abbvie, Inc.’s (ABBV - Free Report) Humira (adalimumab) monotherapy in adult patients with moderate to severely active RA who were refractory to, intolerant to or inappropriate for methotrexate. Results showed that sirukumab monotherapy achieved the first two co-primary endpoints, having led to a significant improvement in disease activity compared with Humira monotherapy.
We note that regulatory applications seeking approval for sirukumab for RA have been filed in both the U.S. and the EU.
Glaxo is developing sirukumab under a licensing and co-development agreement with Johnson & Johnson’s (JNJ - Free Report) Janssen Biologics.
In a separate press release, Glaxo announced data from a seven-year safety and efficacy continuation phase III study on Benlysta for the treatment of patients with active, autoantibody-positive systemic lupus erythematosus (SLE). Data showed that long-term control of disease activity in patients receiving Benlysta plus standard of care led to meaningful benefits in their daily lives, including improvements in health-related quality of life and fatigue.
Data from the studies on sirukumab and Benlysta will be presented at the annual meeting of the American College of Rheumatology/Association for Rheumatology Health Professionals.
Glaxo currently carries a Zacks Rank #3 (Hold)
GLAXOSMITHKLINE Price
GLAXOSMITHKLINE Price | GLAXOSMITHKLINE Quote
A Stock to Consider
A better-ranked stock in the healthcare sector is Anika Therapeutics (ANIK - Free Report) . The company sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has gained 17.1% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>